Orphazyme A/S: Reporting of transactions made by p
Post# of 301275
(Total Views: 75)
Posted On: 11/16/2017 5:00:25 AM
Orphazyme A/S: Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Orphazymes' shares
Attachments:
| Company announcement | Orphazyme A/S |
| No. 9/2017 | Ole Maaløes Vej 3 |
| DK-2200 Copenhagen N | |
| www.orphazyme.com | |
| Company Registration No. 32266355 | |
| 16 November 2017 |
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 ("Orphazyme"), hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in Orphazyme and persons closely associated with them in Orphazymes' shares in connection with the Initial Public Offering:
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Georges Gemayel | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chairman of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 87,758 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Bo Jesper Hansen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Deputy Chairman of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 29,445 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Bo Jesper Hansen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Deputy Chairman of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 50,000 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Bohrs Tower IVS | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Martin Bonde, member of the board of directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 42,884 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | |||
| a) | Name | Martin Bonde | ||
| 2 | Reason for the notification | |||
| a) | Position/status | Member of the Board of Directors | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | |||
| a) | Name | Orphazyme A/S | ||
| b) | LEI code | 54930025OZD2GGSQ7L42 | ||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | ||
| b) | Nature of the transaction | Subscription for shares | ||
| c) | Price(s) and volume(s) | Price (s) | Volume(s) | |
| 80.00 | 3,125 | |||
| d) | Aggregated information Aggregated volume Price | |||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | ||
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | ||
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Rahbek Kornum IVS | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Martin Rahbek Kornum, member of the Board of Directors (resigned 16 November 2017) | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 22,726 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Catherine Moukheibir | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 7,980 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Anders Hedegaard | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 6,250 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Kurma Biofund II | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Rémi Droller, member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 139,578 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | LSP V Cöoperatieve U.A. | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Martijn Kleijwegt, member of the Board of Directors | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 279,157 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | WoB Holding IVS | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Anders Hinsby, Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 180,846 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Anders Hinsby | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 5,000 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Alpha Healthcare Investments ApS | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Anders Vadsholt, Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 121,556 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Anders Vadsholt | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 6,250 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Dare to Dream IVS | |
| 2 | Reason for the notification | ||
| a) | Position/status | Closely Associated Person to Thomas Kirkegaard Jensen, Chief Scientific Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 156,535 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Thomas Kirkegaard Jensen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Scientific Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 4,000 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Thomas Blaettler | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Medical Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060910917 | |
| b) | Nature of the transaction | Exercise of warrants for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 1.00 | 108,502 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| 1 | Details of the Reporting Person / Closely Associated Person | ||
| a) | Name | Thomas Blaettler | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Medical Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Orphazyme A/S | |
| b) | LEI code | 54930025OZD2GGSQ7L42 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument and identification code | Shares ISIN DK0060911055 | |
| b) | Nature of the transaction | Subscription for shares | |
| c) | Price(s) and volume(s) | Price (s) | Volume(s) |
| 80.00 | 1,875 | ||
| d) | Aggregated information Aggregated volume Price | ||
| e) | Date of the transaction | 2017-11-16 09:00 UTC+1 | |
| f) | Place of the transaction | Nasdaq Copenhagen A/S - XCSE | |
| For additional information, please contact | |
| Orphazyme | |
| Anders Vadsholt, CFO | +45 28 98 90 55 |
(0)
(0)Scroll down for more posts ▼